Роботи, що індексуються в Google Scholar
FINDRISC SCALE AS A TOOL FOR ASSESSING THE RISK OF LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Опубліковано 19.03.2024
Як цитувати
Parpibaeva , D., & Musaeva , M. (2024). FINDRISC SCALE AS A TOOL FOR ASSESSING THE RISK OF LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Матеріали конференцій МЦНД, (15.03.2024; Чернівці, Україна), 153–154. вилучено із https://archive.mcnd.org.ua/index.php/conference-proceeding/article/view/1100
Завантаження
Дані завантаження ще не доступні.
Авторське право (c) 2024 Dinora Parpibaeva , Mukharram Musaeva
Ця робота ліцензується відповідно до Creative Commons Attribution-ShareAlike 4.0 International License.
Анотація
Non-alcoholic fatty liver disease is a common chronic disease that combines clinical and morphological changes in the liver: steatosis, non-alcoholic steatohepatitis, fibrosis and a possible outcome in liver cirrhosis. NAFLD is a complex group of various morphological changes in liver tissue due to metabolic changes and is characterized by the accumulation of fat droplets.
Посилання
- Almpanis Z. Evaluation of liver fibrosis: “Something old, something new…” // Ann. Gastroenterol. 2016. Vol. 29. 445-453.
- Abenavoli L., Beaugrand M. Transient elastography in non-alcoholic fatty liver disease // Ann. Hepatol. 2012. Vol. 11. P. 172-178.
- Cai C, Lin Y, Yu C. Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Can J Gastroenterol Hepatol 2019; 2019: 2096161. [PMC free article] [PubMed] [Google Scholar].
- Festi D., Schiumerini R., Marzi L. et al. Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of noninvasive methods // Alim. Pharmacol. Ther. 2013. Vol. 37. P. 392-400.
- Mayo Clinic gastroenterology and hepatology board review. Editor-in-chief S.C.Hauser; associate editors A.S.Oxentenko, W.Sanchez. 5th edition. 2015.